Profile data is unavailable for this security.
About the company
Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function, and drug abuse. The Company’s products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.
- Revenue in GBP (TTM)13.60m
- Net income in GBP8.67m
- Incorporated2003
- Employees16.00
- LocationBioventix PLC7 Romans Business Park, East StreetFARNHAM GU9 7SXUnited KingdomGBR
- Phone+44 125 272 8001
- Fax+44 125 272 8002
- Websitehttps://www.bioventix.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Futura Medical PLC | 3.10m | -6.51m | 112.59m | 12.00 | -- | 20.55 | -- | 36.31 | -0.0219 | -0.0219 | 0.0105 | 0.0182 | 0.3391 | -- | 5.09 | 258,414.20 | -71.22 | -79.25 | -127.75 | -127.22 | 57.22 | -- | -210.03 | -914.37 | 1.47 | -- | 0.00 | -- | -- | -- | -11.40 | -- | 219.68 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -26.33m | 133.23m | 34.00 | -- | -- | -- | -- | -0.4038 | -0.4038 | 0.00 | -0.1876 | 0.00 | -- | -- | 0.00 | -287.97 | -213.06 | -- | -963.12 | -- | -- | -- | -- | -- | -12.02 | -- | -- | -- | -- | -7.71 | -- | -16.05 | -- |
| Avacta Group Plc | 16.03m | -42.08m | 145.05m | 120.00 | -- | 4.89 | -- | 9.05 | -0.1605 | -0.1633 | 0.0606 | 0.0826 | 0.2406 | 4.50 | 2.38 | 133,541.70 | -63.18 | -- | -119.23 | -- | 54.40 | -- | -262.60 | -- | 0.6603 | -1.66 | 0.6913 | -- | 228.22 | -- | -49.92 | -- | -- | -- |
| Animalcare Group Plc | 74.35m | 1.20m | 147.31m | 226.00 | 124.17 | 1.88 | 16.54 | 1.98 | 0.0197 | 0.0197 | 1.23 | 1.30 | 0.6608 | 2.63 | 5.54 | 328,986.70 | 1.07 | 0.3272 | 1.30 | 0.3866 | 58.30 | 53.90 | 1.61 | 0.5484 | 1.05 | 6.35 | 0.0701 | 599.95 | 3.82 | 0.5138 | -38.98 | -- | -11.79 | 2.59 |
| 4Basebio PLC | 354.00k | -6.28m | 179.27m | -- | -- | 50.56 | -- | 506.42 | -0.5094 | -0.5094 | 0.0287 | 0.2769 | 0.0296 | 0.3977 | 4.88 | -- | -52.42 | -- | -60.21 | -- | 80.51 | -- | -1,772.60 | -- | 3.28 | -40.29 | 0.6683 | -- | -20.71 | -- | -59.20 | -- | -- | -- |
| hVIVO PLC | 56.04m | 16.12m | 182.34m | 274.00 | 11.46 | 5.31 | 9.68 | 3.25 | 0.0234 | 0.0234 | 0.0817 | 0.0505 | 0.8327 | -- | 4.08 | 204,536.50 | 23.94 | -0.643 | 46.27 | -1.29 | -- | -- | 28.75 | -0.765 | 1.47 | -- | 0.2674 | -- | 15.61 | 35.40 | 2,176.68 | -- | 136.55 | -- |
| Allergy Therapeutics plc | 53.26m | -50.22m | 193.04m | 635.00 | -- | 7.30 | -- | 3.62 | -0.0266 | -0.0266 | 0.017 | 0.0056 | 0.7571 | 2.21 | 4.92 | 83,870.87 | -71.39 | -11.59 | -102.10 | -15.15 | 52.54 | 70.08 | -94.29 | -11.78 | 0.9281 | -7.93 | 0.2713 | -- | -18.11 | -2.71 | -212.65 | -- | 16.41 | -- |
| Alliance Pharma plc | 170.05m | -7.06m | 209.68m | 249.00 | -- | 0.7567 | 66.95 | 1.23 | -0.0131 | -0.0131 | 0.3145 | 0.5127 | 0.3202 | 2.88 | 4.40 | 682,927.70 | -1.33 | 2.64 | -1.47 | 2.95 | 57.58 | 63.38 | -4.15 | 8.35 | 1.38 | 2.18 | 0.31 | 53.41 | 2.58 | 10.50 | -87.21 | -49.62 | -25.78 | 5.94 |
| Bioventix PLC | 13.60m | 8.67m | 224.45m | 16.00 | 26.34 | 19.63 | 25.54 | 16.51 | 1.63 | 1.63 | 2.56 | 2.19 | 1.09 | 1.53 | 2.54 | 849,780.60 | 69.72 | 56.43 | 79.03 | 61.01 | 93.75 | 92.64 | 63.73 | 65.08 | 6.69 | -- | 0.00 | 84.49 | 9.36 | 7.93 | 9.10 | 8.13 | -37.12 | 20.03 |
| Niox Group PLC | 36.80m | 9.50m | 299.38m | 85.00 | 33.40 | 3.31 | 21.54 | 8.14 | 0.0211 | 0.0238 | 0.0819 | 0.2136 | 0.3874 | 2.31 | 6.13 | 432,941.20 | 10.00 | -2.41 | 10.57 | -2.90 | 72.01 | 70.87 | 25.82 | -11.46 | 3.99 | -- | 0.013 | -- | 17.57 | -5.29 | -32.62 | -- | -5.59 | -- |
| Oxford BioMedica plc | 89.54m | -157.49m | 331.00m | 714.00 | -- | 4.33 | -- | 3.70 | -1.63 | -1.63 | 0.9273 | 0.7645 | 0.2513 | 3.91 | 3.07 | 125,404.80 | -51.69 | -19.60 | -64.26 | -24.68 | 44.37 | 50.74 | -205.68 | -44.38 | 2.90 | -22.92 | 0.5888 | -- | -36.04 | 6.04 | -302.20 | -- | -0.6307 | -- |
Data as of Jun 03 2024. Currency figures normalised to Bioventix PLC's reporting currency: UK Pound GBX
49.20%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Sanford DeLand Asset Management Ltd.as of 10 Apr 2024 | 619.50k | 11.87% |
| Liontrust Investment Partners LLPas of 27 Oct 2023 | 574.16k | 11.00% |
| Link Fund Solutions Ltd.as of 31 Jan 2024 | 363.63k | 6.97% |
| Gresham House Asset Management Ltd. (Investment Management)as of 01 Sep 2023 | 289.00k | 5.54% |
| Rathbones Investment Management Ltd.as of 27 Oct 2023 | 164.94k | 3.16% |
| Investec Wealth & Investment Ltd.as of 01 Sep 2023 | 145.00k | 2.78% |
| Joh. Berenberg, Gossler & Co. KG (Investment Management)as of 28 Apr 2023 | 127.90k | 2.45% |
| Hargreaves Lansdown Asset Management Ltd.as of 01 Sep 2023 | 114.00k | 2.18% |
| EdenTree Investment Management Ltd.as of 01 Sep 2023 | 100.00k | 1.92% |
| Walker Crips Investment Management Ltd.as of 01 Sep 2023 | 70.00k | 1.34% |
More ▼
Data from 29 Sep 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
